 The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate MTX and etanercept or adalimumab in participants with active rheumatoid arthritis RA. The secondary objective was to explore the efficacy of rituximab in combination with MTX and etanercept or adalimumab in participants with active RA. 